(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
During differentiation into eosinophils, eosinophil-lineage committed progenitors (EoPs) go through intermediate stages prior to reaching maturity. A number of stimulatory and inhibitory factors regulate these events. We have developed ex vivo culture methods to differentiate EoPs into mature eosinophils in order to identify novel regulators of eosinophil development (i.e. eosinophilopoiesis). We can also apply these methods to study genetic modifications of EoPs and the downstream effects on eosinophilopoiesis, as well as to generate large numbers of mature cells to investigate eosinophil effector functions.
Furthermore, eosinophils are exquisitely sensitive to their local microenvironment through expression of a plethora of receptors for cytokines, lipids and microbial products. Our high-yield culture methods allow for investigations into the regulation of these environmental sensors. These investigations could provide insight into eosinophil functional responses, such as the local degranulation and release of cytotoxic proteins, in tissues such as the lung in a patient with asthma or the esophagus in a patient with eosinophilic esophagitis (EoE).
Generation of eosinophils from cryopreserved murine bone marrow cells
IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation
Targeting eosinophils in allergy, inflammation and beyond
2013 ARTrust™ Faculty Development Award7/01/2013-6/30/2016Funding Agency: American Academy of Allergy, Asthma and Immunology (AAAAI)Project Title: Regulation of Eosinophil Progenitors by Toll-like ReceptorsPrincipal Investigator: Patricia C. Fulkerson, MD, PhD
K08 KAI093573A04/01/11-03/31/16Funding Agency: National Institutes of HealthProject Title: Role of Spi-C in Eosinophil Development and Functional ResponsesPrincipal Investigator: Patricia C. Fulkerson, MD, PhD
Recently, therapeutics that target eosinophils, by blocking specific steps of eosinophil development, migration or activation, have entered clinical testing and are having promising results.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center